

# Daniel Hochhauser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250072/publications.pdf>

Version: 2024-02-01

94  
papers

7,027  
citations

81900

39  
h-index

60623

81  
g-index

129  
all docs

129  
docs citations

129  
times ranked

10925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	27.0	1,521
2	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018, 392, 123-133.	13.7	984
3	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	7.1	366
4	EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment. <i>Cancer Research</i> , 2011, 71, 1103-1114.	0.9	249
5	Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 821-831.	9.4	227
6	Mechanisms of Multidrug Resistance in Cancer Treatment. <i>Acta Oncologica</i> , 1992, 31, 205-213.	1.8	189
7	Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. <i>British Journal of Cancer</i> , 2010, 102, 1106-1112.	6.4	173
8	A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. <i>British Journal of Cancer</i> , 2002, 87, 600-607.	6.4	151
9	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. <i>Lancet Oncology, The</i> , 2004, 5, 409-418.	10.7	143
10	Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1877-1884.	1.6	138
11	SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity. <i>Cancer Research</i> , 2004, 64, 6693-6699.	0.9	123
12	The diagnosis and management of gastric cancer. <i>BMJ, The</i> , 2013, 347, f6367-f6367.	6.0	122
13	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1252-1259.	6.4	121
14	Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. <i>Blood</i> , 2002, 100, 224-229.	1.4	120
15	Communication with children and adolescents about the diagnosis of their own life-threatening condition. <i>Lancet, The</i> , 2019, 393, 1150-1163.	13.7	100
16	Communication with children and adolescents about the diagnosis of a life-threatening condition in their parent. <i>Lancet, The</i> , 2019, 393, 1164-1176.	13.7	99
17	Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 10436-10440.	7.1	98
18	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 209-218.	4.1	96

#	ARTICLE	IF	CITATIONS
19	Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839). <i>Clinical Cancer Research</i> , 2004, 10, 6476-6486.	7.0	79
20	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	12.1	73
21	Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 2140-2147.	7.0	68
22	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
23	WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway. <i>Nature Communications</i> , 2015, 6, 7324.	12.8	63
24	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 378-378.	1.6	59
25	Structure of the human DNA repair gene HAP1 and its localisation to chromosome 14q 11.2. <i>Nucleic Acids Research</i> , 1992, 20, 4417-4421.	14.5	58
26	Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3015-3023.	4.1	55
27	mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. <i>Cell Death and Differentiation</i> , 2017, 24, 1045-1062.	11.2	55
28	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score $\geq 10$ . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
29	Inhibition of DNA binding of the NF- $\kappa$ B transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1319-1328.	4.1	52
30	$\gamma$ -H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000). <i>Clinical Cancer Research</i> , 2013, 19, 721-730.	7.0	52
31	Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1442-1454.	1.6	52
32	Transcriptional Regulation of Topoisomerase II $\alpha$ at Confluence and Pharmacological Modulation of Expression by bis-Benzimidazole Drugs. <i>Molecular Pharmacology</i> , 2001, 59, 699-706.	2.3	51
33	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). <i>Clinical Cancer Research</i> , 2015, 21, 5563-5577.	7.0	51
34	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv394.	6.3	50
35	NF- $\kappa$ B activates genes of metabolic pathways altered in cancer cells. <i>Oncotarget</i> , 2016, 7, 1633-1650.	1.8	50
36	A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O <sup>6</sup> -Methylguanine-DNA Methyltransferase Promoter. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 809-818.	4.1	48

#	ARTICLE	IF	CITATIONS
37	Liver resection surgery versus thermal ablation for colorectal Liver Metastases (LAVA): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 105.	1.6	45
38	The role of topoisomerase II $\alpha$ and II $\beta$ in drug resistance. <i>Cancer Treatment Reviews</i> , 1993, 19, 181-194.	7.7	42
39	Relevance of mitochondrial DNA in cancer. <i>Lancet</i> , The, 2000, 356, 181-182.	13.7	40
40	Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 1255-1264.	0.9	39
41	Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2019, 25, 2471-2482.	7.0	32
42	Targeting the Inverted CCAAT Box 2 in the Topoisomerase II $\alpha$ Promoter by JH-37, an Imidazole $\alpha$ -Pyrrole Polyamide Hairpin: Design, Synthesis, Molecular Biology, and Biophysical Studies. <i>Biochemistry</i> , 2004, 43, 12249-12257.	2.5	30
43	An Extended Pyrrolobenzodiazepine $\alpha$ -Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6339-6351.	6.4	30
44	Small molecule drugs $\alpha$ optimizing DNA damaging agent-based therapeutics. <i>Current Opinion in Pharmacology</i> , 2012, 12, 398-402.	3.5	29
45	Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC $\alpha$ ONC Study $\alpha$ A Single $\alpha$ Center, Blinded, Randomized Controlled Trial. <i>Clinical Cardiology</i> , 2016, 39, 72-82.	1.8	29
46	Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095680.	3.2	29
47	Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage. <i>Clinical Cancer Research</i> , 2014, 20, 3496-3506.	7.0	28
48	Modulation of topoisomerase II $\alpha$ expression by a DNA sequence-specific polyamide. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 346-354.	4.1	27
49	MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. <i>Oncotarget</i> , 2018, 9, 11592-11603.	1.8	27
50	Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. <i>Oncotarget</i> , 2015, 6, 10548-10562.	1.8	26
51	Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. <i>Anti-Cancer Drugs</i> , 1997, 8, 903-910.	1.4	25
52	Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM). <i>Medicine (United States)</i> , 2016, 95, e2924.	1.0	24
53	Targeting the ICB2 site of the topoisomerase II $\alpha$ promoter with a formamido-pyrrole $\alpha$ -imidazole $\alpha$ -pyrrole H-pin polyamide. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5553-5561.	3.0	23
54	Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1305-1312.	6.4	23

#	ARTICLE	IF	CITATIONS
55	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 149.	3.0	23
56	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. <i>Scientific Reports</i> , 2020, 10, 663.	3.3	23
57	Binding of f-PIP, a pyrrole- and imidazole-containing triamide, to the inverted CCAAT box-2 of the topoisomerase III $\pm$ promoter and modulation of gene expression in cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 6161-6164.	2.2	21
58	Evidence for different mechanisms of "unhooking"™ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. <i>BMC Cancer</i> , 2012, 12, 436.	2.6	20
59	Targeting the inverted CCAAT Box-2 of the topoisomerase III $\pm$ gene: DNA sequence selective recognition by a polyamide "intercalator as a staggered dimer. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2093-2102.	3.0	18
60	Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-38.	2.8	17
61	Effects of wild-type p53 expression on the quantity and activity of topoisomerase II $\beta$ and $\alpha$ in various human cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 1999, 75, 245-257.	2.6	16
62	The role of 99mTc-depreotide in the management of neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2008, 29, 436-440.	1.1	16
63	Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide. <i>Chemistry and Biology</i> , 2015, 22, 862-875.	6.0	15
64	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCA<math>m</math>).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4152-TPS4152.	1.6	15
65	Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4115-4115.	1.6	15
66	Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1239-1245.	5.0	14
67	Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase III $\pm$ Expression. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2897-2908.	4.1	12
68	Design of a Hairpin Polyamide, ZT65B, for Targeting the Inverted CCAAT Box (ICB) Site in the Multidrug Resistant (MDR1) Gene. <i>ChemBioChem</i> , 2005, 6, 2305-2311.	2.6	11
69	Stress-specific p38 MAP kinase activation is sufficient to drive EGF receptor endocytosis but not nuclear translocation. <i>Journal of Cell Science</i> , 2017, 130, 2481-2490.	2.0	11
70	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 669-669.	1.6	11
71	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4-LBA4.	1.6	11
72	Synthesis and Evaluation of an Intercalator-Polyamide Hairpin Designed to Target the Inverted CCAAT Box 2 in the Topoisomerase III $\pm$ Promoter. <i>ChemBioChem</i> , 2006, 7, 1722-1729.	2.6	10

#	ARTICLE	IF	CITATIONS
73	Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomesâ€”The University College London Hospital (UCLH) Experience. <i>Cancers</i> , 2020, 12, 3545.	3.7	9
74	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4049-4049.	1.6	9
75	Modulation of topoisomerase III $\pm$ expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 617-629.	1.9	8
76	Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter. <i>Cell Cycle</i> , 2017, 16, 1855-1856.	2.6	7
77	The role of PARP inhibitors in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103621.	4.4	7
78	Phorbol ester-induced down-regulation of topoisomerase III $\pm$ mRNA in a human erythroleukemia cell line. <i>Biochemical Pharmacology</i> , 1996, 52, 1065-1072.	4.4	5
79	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacyâ€”Response. <i>Clinical Cancer Research</i> , 2016, 22, 2595-2595.	7.0	4
80	Effects of wildâ€”type p53 expression on the quantity and activity of topoisomerase III $\pm$ and I $\beta$ 2 in various human cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 1999, 75, 245-257.	2.6	4
81	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4032-4032.	1.6	4
82	Abstract 1766: Persistence of drug-induced DNA interstrand cross-links distinguishes bendamustine from conventional DNA cross-linking agents. , 2012, , .		3
83	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. <i>International Journal of Oncology</i> , 2005, 27, 337.	3.3	2
84	Molecular biologists map pathways to gastrointestinal cancer. <i>Lancet, The</i> , 1998, 351, 1109.	13.7	1
85	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. <i>Drug Discovery Today: Disease Models</i> , 2012, 9, e69-e73.	1.2	1
86	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 412-412.	1.6	1
87	Effects of N-terminus modified Hx-amides on DNA binding affinity, sequence specificity, cellular uptake, and gene expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128158.	2.2	1
88	261â€”...Association of T-cellâ€”inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180. , 2020, , .		1
89	Colon cancer genotypes change in two ways. <i>Lancet, The</i> , 1997, 349, 1151.	13.7	0
90	Arsenic compound effective in leukaemia. <i>Lancet, The</i> , 1998, 351, 1037.	13.7	0

#	ARTICLE	IF	CITATIONS
91	Abstract 665: Targeting the Mlul cell cycle box (MCB) sequence 5â€™-ACGCGT-3â€™ in the human Dbf4 promoter using the rationally designed polyamide formamido-imidazole-pyrrole-imidazole (f-PI). , 2011, , .		0
92	Abstract 5468: Interaction between cetuximab and chemotherapy in colon cancer.. , 2013, , .		0
93	Abstract 3596: A biomarker study of lapatinib in the neoadjuvant treatment of HER2 over expressing esophago-gastric adenocarcinoma (EGA). , 2015, , .		0
94	Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).. Journal of Clinical Oncology, 2019, 37, 4048-4048.	1.6	0